Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of “Hold” by Brokerages

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned a consensus rating of “Hold” from the eight analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $5.34.

Several research analysts have recently issued reports on the company. Wall Street Zen upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Wells Fargo & Company raised their price target on shares of Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Zacks Research cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research note on Monday.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. grew its holdings in Ironwood Pharmaceuticals by 30.2% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,920,530 shares of the biotechnology company’s stock worth $2,516,000 after acquiring an additional 445,484 shares during the period. Public Employees Retirement System of Ohio grew its stake in shares of Ironwood Pharmaceuticals by 351.2% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 60,768 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 47,299 shares during the period. Mercer Global Advisors Inc. ADV increased its holdings in shares of Ironwood Pharmaceuticals by 113.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 71,353 shares of the biotechnology company’s stock valued at $93,000 after purchasing an additional 37,938 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Ironwood Pharmaceuticals by 159.6% during the 3rd quarter. Millennium Management LLC now owns 250,119 shares of the biotechnology company’s stock valued at $328,000 after purchasing an additional 153,787 shares in the last quarter. Finally, Integrated Wealth Concepts LLC lifted its stake in shares of Ironwood Pharmaceuticals by 21.4% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the period.

Ironwood Pharmaceuticals Trading Down 0.3%

NASDAQ:IRWD opened at $3.16 on Friday. The company has a market capitalization of $513.29 million, a P/E ratio of -63.19 and a beta of 0.37. Ironwood Pharmaceuticals has a 12 month low of $0.53 and a 12 month high of $5.13. The firm has a fifty day simple moving average of $1.86 and a 200-day simple moving average of $1.19.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The company had revenue of $122.06 million during the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current year.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.